Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065

Status	RECRUITING
Phase	Phase 3
Sponsor	AbbVie
Enrollment	561 participants

Key Eligibility Criteria

Inclusion (4)

- Pseudophakic (at least 12 weeks post cataract surgery at Screening Visit 1 \[Week -6\]) in the study eye.
- Must have a diagnosis of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye
- CNV lesion characteristics as assessed by the central reading center: lesion size needs to be less than 10-disc areas (typical disc area = 2.54 mm\^2)
- Must have received at least 2 intravitreal anti-vascular endothelial growth factor (VEGF) injections in the past 6 months in the study eye prior to Screening Visit 1 (Week -6) and have been responsive (determined by investigator)

Exclusion (5)

- CNV or macular edema in the study eye that is secondary to any causes other than AMD
- Study eye with nAMD diagnosed \> 4 years from Screening Visit 1
- Any retinal pigment epithelial detachment \> 400 µm or any pigment epithelial detachment \> 350 µm within the central subfield (central 1 mm) in the study eye at Screening Visit 1 (Week -6), as assessed by the central reading center.
- Any subretinal hemorrhage in the study eye \> 50% of the total lesion area or within the parafovea (3 mm center of the macula), as determined by the central reading center
- Retinal pigment epithelial tear involving the central subfield (central 1 mm) in the study eye as determined by the central reading center.

Locations (95 total)

Barnet Dulaney Perkins Eye Centers /ID# 279265, Mesa, Arizona, United States
American Vision Partners /ID# 264615, Sun City, Arizona, United States
Retinal Diagnostic Center /ID# 263054, Campbell, California, United States
... and 92 more locations